Company profile
Inoviv | Biomarker Development
Inoviv biomarker tests to support novel therapies
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
AD01 | Transaction MzUyMzYxOTg5MmFkaXF6a2N4
Published 26 May 2026 07:49
CS01 | Transaction MzUxNDc4ODY2N2FkaXF6a2N4
Published 07 Apr 2026 17:49
PSC07 | Transaction MzUxNDc4Mzc0M2FkaXF6a2N4
Published 07 Apr 2026 16:25
TM01 | Transaction MzUxNDc3OTI5NmFkaXF6a2N4
Published 07 Apr 2026 15:46
PSC07 | Transaction MzUxNDc3OTE4MmFkaXF6a2N4
Published 07 Apr 2026 15:46
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Aug 2020 to 28 Feb 2021
There is no easily accessible COVID-19/SARS-CoV-2 antibody test with adequate sensitivity and specificity. This hampers diagnosis, contact tracing and policy decisions. We have initiated the development of 2 targeted mass spectrometry (MS) antibody tests for mass-testing and vaccine development. These saliva and plasma tests are rapidly scalable, automate...
1 May 2020 to 31 Aug 2020
Our innovation is the development of a new test for COVID-19/SARS-CoV-2 human antibodies to detect immunity. The test is rapidly scalable, highly automated, can be readily transferred and standardised across multiple instruments, manufacturers and laboratories. It has high inherent specificity and sensitivity in contrast to existing tests, reducing the fa...
